-Huperzine A using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA NPs (Lf-TMC NPs) were developed for intranasal delivery to the brain for the treatment of AD. After intranasal administration, Lf-TMC NPs facilitated the distribution of HupA in the brain, and the values of the drug targeting index in the mouse olfactory bulb, cerebrum (with hippocampus removal), cerebellum, and hippocampus were about 2.0, 1.6, 1.9, and 1.9, respectively. This evidence concerns the gene LTF and Alzheimer disease.